The Centers for Disease Control and Prevention is investigating the possible link of gum medications treatment with Alzheimer’s.
The researchers, led by researchers at the National Institute of Neurological Disorders and Stroke, said in a statement on Monday that they hope to have more details about the findings in the coming months.
They said that the study, published in the journal Neurology, looked at data from more than 20,000 adults who had taken gum medication and compared the effects of different doses of gum with a control group of the same people.
The study also looked at the effect of a drug called dasatinib, which was approved in March to treat Alzheimer’s and other forms of dementia.
The drug was approved by the Food and Drug Administration in April 2018.
The research is part of the CDC’s effort to understand how and why some medications affect the brain.
The agency said it was investigating the possibility that the medications might affect Alzheimer’s patients’ cognitive functioning.